Claude P Genain

US Patent:

6569431, May 27, 2003

Filed:

Jul 5, 2001

Appl. No.:

09/899896

Inventors:

Claude P. Genain - Mill Valley CA
Stephen L. Hauser - Ross CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39395

US Classification:

4241421, 4241301, 4241331, 4241371, 4241411, 4241431, 4241521, 4241721, 5303871, 5303873, 5303875, 5303881, 53038815, 5303882, 53038822

Abstract:

The invention provides methods and compositions for inhibiting autoantibody binding in demyelinating disease such as multiple sclerosis. The compositions comprise immunoglobulin CDR3 sequences derived from combinatorial phage display libraries selected for high-affinity binding to myelin oligodendrocyte glycoprotein.

US Patent:

6573236, Jun 3, 2003

Filed:

Dec 21, 2001

Appl. No.:

10/026045

Inventors:

Claude P. Genain - Mill Valley CA
Stephen L. Hauser - Ross CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 3804

US Classification:

514 2, 514 15, 514 16, 514 17, 514903, 536300, 536328, 536329, 4241841

Abstract:

The invention provides methods and compositions for inhibiting pathogenic binding of an pathogenic autoantibody to a myelin oligodendrocyte glycoprotein (MOG) autoantigen and screening for inhibitors of pathogenic binding of an autoantibody to a MOG autoantigen.

US Patent:

7282482, Oct 16, 2007

Filed:

May 10, 2001

Appl. No.:

09/854142

Inventors:

Ilse Bartke - Mannheim, DE
Jurgen Unger - Landshut, DE
Claude Genain - Mill Valley CA, US
Stephen Hauser - Ross CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 38/18

US Classification:

514 12, 514 2

Abstract:

This invention pertains to the discovery that nerve growth factor (NGF) is capable of preventing further demyelination of nervous tissue in pathologies characterized by the demyelination of nervous tissue (e. g. multiple sclerosis). In one embodiment, this invention provides a method for inhibiting demyelination in a subject having an inflammatory disease of a nervous tissue. The method involves administering an effective amount of NGF, an NGF analogue, or an active fragment of NGF where the effective amount is sufficient to downregulate the production of interferon λ by T cells infiltrating the central nervous system and/or to upregulate IL-10 production by glial cells.

US Patent:

20050009096, Jan 13, 2005

Filed:

Oct 10, 2003

Appl. No.:

10/683451

Inventors:

Claude Genain - Mill Valley CA, US
Hans-Christian Von Budingen - Schlier, DE
Til Menge - San Francisco CA, US

International Classification:

G01N033/53

US Classification:

435007100

Abstract:

This invention provides methods utilizing detection/quantification of autoantibodies to specific epitopes of myelin components (e.g. to conformational epitope of myelin/oligodendrocyte glycoprotein (MOG)) for the definitive diagnosis, and/or staging or typing, and/or prognosis of multiple sclerosis.

US Patent:

20060130161, Jun 15, 2006

Filed:

Oct 12, 2005

Appl. No.:

11/248499

Inventors:

Claude Genain - Mill Valley CA, US

Assignee:

CARANTECH, INC. - Mill Valley CA

International Classification:

A01K 67/027

US Classification:

800009000, 800014000

Abstract:

Provided are non-human animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and autoimmune diseases such as diseases of the central nervous system, including multiple sclerosis (MS), and diabetes. Such non-human animal model systems may be suitably employed for the study of diseases such as MS and diabetes and for the identification and characterization of candidate therapeutic compounds and compositions for the treatment of such diseases. Also provided herein are markers and methods for the detection, in patients susceptible to autoimmune disease, of autoimmune diseases of the central nervous system such as progressive multifocal leukoencephalopathy (PML) following treatment with one or more therapeutic agent as exemplified herein by the therapeutic agent natalizumab. Exemplary animal model systems comprise marmosets infected with a herpesvirus such as HHV6-A and HHV6-B, transgenic mouse and zebrafish animal model systems wherein the transgene encodes CD46, and methods for monitoring the risks of patients having MS, diabetes and other auto-immune disorders treated with anti-adhesion molecules such as natalizumab.

US Patent:

63330334, Dec 25, 2001

Filed:

Aug 26, 1999

Appl. No.:

9/384036

Inventors:

Claude P. Genain - Mill Valley CA
Stephen L. Hauser - Ross CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39395

US Classification:

4241371

Abstract:

The invention provides methods and compositions for inhibiting pathogenic binding of an pathogenic autoantibody to a myelin oligodendrocyte glycoprotein (MOG) autoantigen and screening for inhibitors of pathogenic binding of an autoantibody to a MOG autoantigen.